Eloralintide weight loss study for adults with excess weight and type 2 diabetes
Tests eloralintide against placebo for weight loss in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Key facts
- Where
- Ansan-si, Guri-si, Gwangju, Seongnam, and Seoul, South KoreaSee the 5 sites
- Phase
- Phase 3
Where in South Korea
- Korea University Ansan HospitalAnsan-si, South KoreaTaking people
- Hanyang University Guri HospitalGuri-si, South KoreaTaking people
- Chosun University HospitalGwangju, South KoreaTaking people
- Seoul National University Bundang HospitalSeongnam, South KoreaTaking people
- Severance Hospital, Yonsei University Health SystemSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07282600EU 2025-523658-15-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Inclusion: Have type 2 diabetes; Are on stable treatment for type 2 diabetes for at least 90 days prior to screening; Have a BMI ≥ 27 kg/m2; Have a stable body weight (<5% body weight change) for 90 days prior to screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any of the following antihyperglycemic medications within 90 days before screening:; amylin analogs; glucagon-like peptide-1 (GLP-1) receptor agonists; glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or; insulin.